Skip to main content
SpringerLink
Log in

Models of acute mucosal tolerance to radiotherapy alone applied to synchronous chemoradiation schedules in head and neck cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Three models defining mucosal tolerance when radiotherapy alone is delivered have been published. Modelling studies have converted the contribution of synchronous chemotherapy to the rate of grade 3 mucositis to biologically effective dose (BED). The purpose of this study was to apply radiotherapy mucosal tolerance models to studies of synchronous chemoradiation. Trials of synchronous cisplatin and radiotherapy were identified. The BED for cell kill for each regime was calculated. Initially, this was done using the protocol parameters and a global value for the contribution of chemotherapy of 5.1 Gy10. These values were then compared with the BED cell kill ceiling values from each of the models calculated using the intended overall treatment time. These steps were then repeated using the delivered radiotherapy parameters and a value for the contribution from chemotherapy calculated to take into account dose intensity. Eight eligible treatment arms were identified. When using the intended radiotherapy parameters, six of these appeared to be tolerable when compared with the ceiling values for two of the models. All were found intolerable by one model. When using the actual delivered radiotherapy doses and overall treatment times and correcting for chemotherapy dose intensity, one treatment arm remained intolerable by all three models, a further treatment arm by two models and four treatment arms by one model. Two current models of mucosal tolerance derived from radiotherapy data predict a majority of previously reported chemoradiation study arms to be tolerable particularly when the delivered parameters are used for calculation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fowler JF, Harari PM, Leborgne F, Leborgne J. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiother Oncol. 2003;69:161–8.

    Article  PubMed  Google Scholar 

  2. Fenwick J, Lawrence G, Malik Z, Nahum A, Mayles W. Early mucosal reactions during and after head-and-neck radiotherapy: dependence of treatment tolerance on radiation dose and schedule duration. Int J Radiat Oncol Biol Phys. 2008;71:625–34.

    Article  PubMed  Google Scholar 

  3. Strigari L, Pedicini P, D'Andrea M, Pinnarò P, Marucci L, Giordano C, et al. A new model for predicting acute mucosal toxicity in head-and-neck cancer patients undergoing radiotherapy with altered schedules. Int J Radiat Oncol Biol Phys. 2012;83:e697–702.

    Article  PubMed  Google Scholar 

  4. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  5. Hartley A, Sanghera P, Glaholm J, Mehanna H, McConkey C, Fowler J. Radiobiological modelling of the therapeutic ratio for the addition of synchronous chemotherapy to radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Clin Oncol. 2010;22:125–30.

    Article  CAS  Google Scholar 

  6. Kasibhatla M, Kirkpatrick JP, Brizel DM. How much radiation is the chemotherapy worth in advanced head and neck cancer? Int J Radiat Oncol Biol Phys. 2007;68:1491–5.

    Article  PubMed  Google Scholar 

  7. Fowler JF. Correction to Kasibhatla, et al. How much radiation is the chemotherapy worth in advanced head and neck cancer? Int J Radiat Oncol Biol Phys 2007; 68:1491–5. Int J Radiat Oncol Biol Phys. 2008;71:326–9.

    Article  PubMed  Google Scholar 

  8. Plataniotis GA, Dale RG. Use of concept of chemotherapy-equivalent biologically effective dose to provide quantitative evaluation of contribution of chemotherapy to local tumour control in chemoradiotherapy cervical cancer trials. Int J Radiat Oncol Biol Phys. 2007;72:1538–43.

    Article  CAS  Google Scholar 

  9. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol. 2006;78:236–44.

    Article  PubMed  CAS  Google Scholar 

  10. Jones B, Sanghera P. Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma. Int J Radiat Oncol Biol Phys. 2007;68:441–8.

    Article  PubMed  Google Scholar 

  11. Jones B, Dale R. The potential for mathematical modeling in the assessment of the radiation dose equivalent of cytotoxic chemotherapy given concomitantly with radiotherapy. Br J Radiol. 2005;78:939–44.

    Article  PubMed  CAS  Google Scholar 

  12. Pettit L, Meade S, Sanghera P, Glaholm J, Geh JI, Hartley A. Can radiobiological parameters derived from squamous cell carcinoma of the head and neck be used to predict local control in anal cancer treated with chemoradiation? Br J Radiol. 2012;86:20120372.

    Article  Google Scholar 

  13. Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer. 2000;88:876–83.

    Article  PubMed  CAS  Google Scholar 

  14. Adelstein DJ, Li Y, Adams GL, Wagner Jr H, Kish JA, Ensley JF, et al. An intergroup phase iii comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–8.

    Article  PubMed  Google Scholar 

  15. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–8.

    Article  PubMed  CAS  Google Scholar 

  16. Bensadoun RJ, Bénézery K, Dassonville O, Magné N, Poissonnet G, Ramaïoli A, et al. French multicentre phase III randomised study testing concurrent twice a day radiotherapy and cisplatin/5-flurouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys. 2006;64:983–94.

    Article  PubMed  CAS  Google Scholar 

  17. Huguenin P, Beer KT, Allal A, Rufibach K, Friedli C, Davis JB, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004;22:4665–73.

    Article  PubMed  CAS  Google Scholar 

  18. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000;18:1458–64.

    PubMed  CAS  Google Scholar 

  19. Ang K, Zhang Q, Wheeler RH, Rosenthal DI, Nguyen-Tan F, Kim H, et al. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome. J Clin Oncol. 2010;28(15 suppl):5507. ASCO Annual Meeting Proceedings (Post-Meeting Edition).

    Google Scholar 

  20. Bhide SA, Gulliford S, Schick U, Miah A, Zaidi S, Newbold K, et al. Dose–response analysis of acute oral mucositis and pharyngeal dysphagia in patients receiving induction chemotherapy followed by concomitant chemo-IMRT for head and neck cancer. Radiother Oncol. 2012;103:88–91.

    Article  PubMed  Google Scholar 

  21. Denham JW, Peters LJ, Johansen J, Poulsen M, Lamb DS, Hindley A, et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol. 1999;52:157–64.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of Interest

None

Author information

Authors and Affiliations

  1. Hall-Edwards Radiotherapy Research Group, Cancer Centre, Queen Elizabeth Hospital, B15 2TH, Birmingham, UK

    Sara Meade, Paul Sanghera, John Glaholm & Andrew Hartley

  2. Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK

    Paul Sanghera, John Glaholm & Andrew Hartley

Authors
  1. Sara Meade
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul Sanghera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Glaholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew Hartley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Hartley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meade, S., Sanghera, P., Glaholm, J. et al. Models of acute mucosal tolerance to radiotherapy alone applied to synchronous chemoradiation schedules in head and neck cancer. Tumor Biol. 35, 2017–2023 (2014). https://doi.org/10.1007/s13277-013-1267-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1267-0

Keywords

Search

Navigation